389 related articles for article (PubMed ID: 32629817)
1. Influence of Herbal Medicines on HMGB1 Release, SARS-CoV-2 Viral Attachment, Acute Respiratory Failure, and Sepsis. A Literature Review.
Wyganowska-Swiatkowska M; Nohawica M; Grocholewicz K; Nowak G
Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32629817
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 and Three Related Coronaviruses Utilize Multiple ACE2 Orthologs and Are Potently Blocked by an Improved ACE2-Ig.
Li Y; Wang H; Tang X; Fang S; Ma D; Du C; Wang Y; Pan H; Yao W; Zhang R; Zou X; Zheng J; Xu L; Farzan M; Zhong G
J Virol; 2020 Oct; 94(22):. PubMed ID: 32847856
[TBL] [Abstract][Full Text] [Related]
3. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using
Choudhary S; Malik YS; Tomar S
Front Immunol; 2020; 11():1664. PubMed ID: 32754161
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting.
Sharifkashani S; Bafrani MA; Khaboushan AS; Pirzadeh M; Kheirandish A; Yavarpour Bali H; Hessami A; Saghazadeh A; Rezaei N
Eur J Pharmacol; 2020 Oct; 884():173455. PubMed ID: 32745604
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin-converting enzyme 2 in severe acute respiratory syndrome coronavirus and SARS-CoV-2: A double-edged sword?
Yan T; Xiao R; Lin G
FASEB J; 2020 May; 34(5):6017-6026. PubMed ID: 32306452
[TBL] [Abstract][Full Text] [Related]
6. Broad and Differential Animal Angiotensin-Converting Enzyme 2 Receptor Usage by SARS-CoV-2.
Zhao X; Chen D; Szabla R; Zheng M; Li G; Du P; Zheng S; Li X; Song C; Li R; Guo JT; Junop M; Zeng H; Lin H
J Virol; 2020 Aug; 94(18):. PubMed ID: 32661139
[TBL] [Abstract][Full Text] [Related]
7. Beta-Adrenergic Blockers as a Potential Treatment for COVID-19 Patients.
Vasanthakumar N
Bioessays; 2020 Nov; 42(11):e2000094. PubMed ID: 32815593
[TBL] [Abstract][Full Text] [Related]
8. The Lung Macrophage in SARS-CoV-2 Infection: A Friend or a Foe?
Abassi Z; Knaney Y; Karram T; Heyman SN
Front Immunol; 2020; 11():1312. PubMed ID: 32582222
[TBL] [Abstract][Full Text] [Related]
9. Natural Flavonoids as Potential Angiotensin-Converting Enzyme 2 Inhibitors for Anti-SARS-CoV-2.
Muchtaridi M; Fauzi M; Khairul Ikram NK; Mohd Gazzali A; Wahab HA
Molecules; 2020 Sep; 25(17):. PubMed ID: 32882868
[TBL] [Abstract][Full Text] [Related]
10. Expression profiling meta-analysis of ACE2 and TMPRSS2, the putative anti-inflammatory receptor and priming protease of SARS-CoV-2 in human cells, and identification of putative modulators.
Gkogkou E; Barnasas G; Vougas K; Trougakos IP
Redox Biol; 2020 Sep; 36():101615. PubMed ID: 32863223
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.
Datta PK; Liu F; Fischer T; Rappaport J; Qin X
Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Hoffmann M; Kleine-Weber H; Schroeder S; Krüger N; Herrler T; Erichsen S; Schiergens TS; Herrler G; Wu NH; Nitsche A; Müller MA; Drosten C; Pöhlmann S
Cell; 2020 Apr; 181(2):271-280.e8. PubMed ID: 32142651
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts.
Zhai X; Sun J; Yan Z; Zhang J; Zhao J; Zhao Z; Gao Q; He WT; Veit M; Su S
J Virol; 2020 Jul; 94(15):. PubMed ID: 32404529
[TBL] [Abstract][Full Text] [Related]
14. Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS).
Cadegiani FA; Goren A; Wambier CG
Med Hypotheses; 2020 Oct; 143():110112. PubMed ID: 32721806
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19).
Bourgonje AR; Abdulle AE; Timens W; Hillebrands JL; Navis GJ; Gordijn SJ; Bolling MC; Dijkstra G; Voors AA; Osterhaus AD; van der Voort PH; Mulder DJ; van Goor H
J Pathol; 2020 Jul; 251(3):228-248. PubMed ID: 32418199
[TBL] [Abstract][Full Text] [Related]
16. Gene expression and
Aguiar JA; Tremblay BJ; Mansfield MJ; Woody O; Lobb B; Banerjee A; Chandiramohan A; Tiessen N; Cao Q; Dvorkin-Gheva A; Revill S; Miller MS; Carlsten C; Organ L; Joseph C; John A; Hanson P; Austin RC; McManus BM; Jenkins G; Mossman K; Ask K; Doxey AC; Hirota JA
Eur Respir J; 2020 Sep; 56(3):. PubMed ID: 32675206
[TBL] [Abstract][Full Text] [Related]
17. Coronaviruses and SARS-COV-2.
Hasöksüz M; Kiliç S; Saraç F
Turk J Med Sci; 2020 Apr; 50(SI-1):549-556. PubMed ID: 32293832
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2.
Gheblawi M; Wang K; Viveiros A; Nguyen Q; Zhong JC; Turner AJ; Raizada MK; Grant MB; Oudit GY
Circ Res; 2020 May; 126(10):1456-1474. PubMed ID: 32264791
[TBL] [Abstract][Full Text] [Related]
19. Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor.
Yang J; Petitjean SJL; Koehler M; Zhang Q; Dumitru AC; Chen W; Derclaye S; Vincent SP; Soumillion P; Alsteens D
Nat Commun; 2020 Sep; 11(1):4541. PubMed ID: 32917884
[TBL] [Abstract][Full Text] [Related]
20. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.
Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY
Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
